Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 (Q37125089)
Jump to navigation
Jump to search
scientific article published on 04 August 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 |
scientific article published on 04 August 2008 |
Statements
1 reference
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 (English)
1 reference
Edith A Perez
1 reference
Lori J Goldstein
1 reference
Anne O'Neill
1 reference
Joseph A Sparano
1 reference
Lawrence N Shulman
1 reference
Silvana Martino
1 reference
Nancy E Davidson
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference